Pharmaceutical composition capable of the incorporation of lenalidomide in various crystalline modifications
JO3333B1
Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
JO3117B1
Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
TN2013000404A1
Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
ZA201307614B
Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
GB201414378D0
Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
CN103608326A
Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
BR112013027075A2
4 - [(haloalkyl) - (dsimethyl) -ammonium] butanoates, preparation processes and their uses in the treatment of cardiovascular disease
EP2578218A1
Antiviral efficacy of disodium 2,6-dimethyl-1,4-dihydropyridine-3,5-bis(carbonyloxyacetate) and its derivatives
EP2422784A1
Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2420289A1
Composition of caffeic acid phenethyl ester (CAPE) and one of catechin, kaempherol and myricetin for potentiating antitumour effect and for treating tumours
EP2425835A1
A new medical use of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate and natural flavonoid derivatives
EP2422848A1
Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422849A1
Composition of Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422815A1
Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
EP2420224A1
Method for producing a stable 3-(2,2,2-trimethylhydrazinium)propionate dihydrate solid pharmaceutical composition
WO2010149654A1
Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt
WO2010133629A1
Stable pharmaceutical composition of fludarabine phosphate
GEP20135819B
3-(2,2,2-trimethylhydrazinium) propionate dihydrate composition of local administration
EP2228365A1
Pharmaceutical combination of 5-fluorouracil and derivative of 1,4-dihydropyridine and its use in the treatment of cancer
